Table 3.
Gene | Transcript | Exon | ||||||||||||
ALL | initial | internal | terminal | single | ||||||||||
sn% | sp% | sn% | sp% | sn% | sp% | sn% | sp% | sn% | sp% | sn% | sp% | sn% | sp% | |
Evigan-5g | 11.9 | 14.4 | 8.7 | 14.4 | 64.5 | 76.8 | 42.3 | 58.4 | 73.3 | 81.5 | 55.8 | 73.1 | 3.6 | 17.4 |
ReRanker-5g | 23.6 | 28.6 | 16.6 | 28.6 | 66.11 | 79.6 | 45.1 | 63.0 | 73.9 | 83.5 | 59.3 | 77.9 | 13.5 | 64.3 |
GeneWise | 18.8 | 21.5 | 14.4 | 21.5 | 56.4 | 75.7 | 32.5 | 49.2 | 66.9 | 88.5 | 41.2 | 55.9 | 9.9 | 14.7 |
Augustus+ | 30.2 | 33.5 | 21.9 | 33.5 | 67.4 | 76.2 | 46.7 | 62.2 | 75.3 | 80.1 | 59.8 | 74.3 | 16.3 | 23.0 |
Evigan-6g | 19.0 | 23.1 | 13.7 | 23.1 | 67.5 | 79.1 | 43.8 | 60.7 | 76.8 | 83.3 | 58.7 | 77.3 | 2.8 | 17.4 |
Performance on the 1746 loci where ReRanker-5g selected a lower probability Evigan-5g model based on cross-species comparison. Note that ReRanker-5g improves on Evigan-5g acrosss the board; italics indicates where other comparative approaches outperform ReRanker-5g (see text).